Vicept Therapeutics Announces Positive Phase II Data Of V-101 For The Treatment Of Type I Rosacea (Erythematotelangiectatic Rosacea)
Links shared publicly online about this topic.
- 586total visits
Vicept Therapeutics Announces Positive Phase II Data Of V-101 For The Treatment Of Type I Rosacea (Erythematotelangiectatic Rosacea)
View full resource at medicalnewstoday.com
Tags: Rosacea, Dairy, Clinical Trial, Relationship
Most Recently Shared on January 12, 2011 at 7:52 pm By:
Vicept Therapeutics Announces Positive Phase II Data Of V-101 For The Treatment Of Type I Rosacea (Erythematotel... http://bit.ly/f4OTDM
Also Shared By:
Vicept Therapeutics Announces Positive Results from a Second Phase II Study of V-101 for the Treatment of Type I Rosacea (Erythematotelangiectatic Rosacea) - Drugs.com MedNews
drugs.com — “-Both Phase II studies achieve statistically significant improvement in primary endpoint of facial redness associated with rosacea- -Safety profile similar to p” View full resource at drugs.com
Most Recently Shared on April 19, 2011 at 2:22 pm By:
Drugs and Devices OW OW Health
Vicept Therapeutics Announces Positive Results from a Second Phase II Study of V-101 for the Treatment of ... http://bit.ly/hMEemk #drug
Vicept reports positive data from V-101 Phase II clinical trial for Type I Rosacea
news-medical.net — “Vicept Therapeutics, Inc. announced today positive study results from a Phase II clinical trial evaluating the dose-response relationship of four concentrations of V-101 cream, a topical cream for the treatment of Type I Rosacea (Erythematotelangiectatic Rosacea). The results demonstrated a statistically significantrebound" or tachyphylaxis was observed.” View full resource at news-medical.net
Most Recently Shared on January 10, 2011 at 2:26 pm By:
Vicept reports positive data from V-101 Phase II clinical trial for Type I Rosacea: Vicept Therapeutics, Inc. an... http://bit.ly/fMvanz
Vicept Therapeutics Announces Positive Phase 2 Data of V-101 for the Treatment of Type I Rosacea (Erythematotelangiectatic Rosacea) - Drugs.com MedNews
drugs.com — “-Highly statistically significant improvement in primary endpoint of facial redness associated with rosacea- Malvern, PA January 10, 2011 Vicept Therapeutics, I” View full resource at drugs.com
Most Recently Shared on January 9, 2011 at 11:16 pm By:
Drugs and Devices OW OW Health
Vicept Therapeutics Announces Positive Phase 2 Data of V-101 for the Treatment of Type I Rosacea (Erythema... http://bit.ly/fl3CLf #drug
Advertisement
MNT Dermatology News
@mnt_dermatology
Vicept Therapeutics Announces Positive Phase II Data Of V-101 For The Treatment Of Type I Rosacea (Erythematotelangiec... http://mnt.to/3PSF
1 year ago...